We prospectively audited blood loss and blood replacement in every child less than 24 months of age undergoing cranioplasty for craniosynostosis in Australia during 2008, in order to obtain more accurate data for the discussion of perioperative transfusion risk. A total of 127 cases were performed at seven centres. There were no directed or autologous blood donations. No patient received preoperative erythropoietin. A total of 233 units of homologous red blood cells were transfused. Overall, 83% of patients received a blood transfusion. This included 100% of patients undergoing cranial vault reconstruction (CVR) and 98% of patients undergoing fronto-orbital advancement (FOA), but only 32% of spring cranioplasty patients. Exposure to no more than one donor was achieved in 60% of FOA patients and 36% of CVR patients. Estimated blood volume loss was more than one blood volume in 36% of CVR and 36% of FOA, but only 12% of spring cranioplasty, and more than two blood volumes in 4% of CVR and 11% of FOA. Differences in surgical technique and volume of surgery between different centres appeared to affect transfusion rates. Children with recognised craniofacial syndromes and those undergoing repeat surgery appeared to have greater blood loss and blood product exposure. There were two cases of sudden massive haemorrhage secondary to dural venous sinus tear, but no death or perioperative cardiac arrest. These findings indicate that blood loss requiring blood product replacement is common in patients <24 months of age undergoing cranioplasty for craniosynostosis, particularly in patients undergoing FOA and CVR.
Craniosynostosis is a condition in which one or more of the fibrous sutures in an infant skull fuses prematurely, and is often associated with abnormal head shape. The premature fusion of skull sutures is assumed to restrict skull and brain growth and predispose to elevated intracranial pressure 1 .
Many of these children undergo cranioplasty to correct the deformity. Surgery is commonly performed in infancy, when the skull is relatively large in proportion to the rest of the body. Several reports suggest that depending on the type of operation it is common for blood loss to be greater than the child's estimated blood volume [2] [3] [4] . There are no published data from Australian hospitals. Nevertheless, the likely blood loss should be considered when determining perioperative risk.
In this audit, we prospectively gathered data about every cranioplasty for craniosynostosis performed in a calendar year in Australia in children aged up to 24 months. We obtained data on blood product exposure and major complications throughout the entire hospital admission. Our aim was to obtain data not only on the absolute risk, but also on factors that might affect the risk.
METHODS
We prospectively audited children aged less than 24 months undergoing cranioplasty for craniosynostosis in Australia in 2008. Ethics committee approval was obtained at each of the participating hospitals. We excluded patients undergoing cranioplasty for reasons other than craniosynostosis and cases where suggested transfusion guidelines were not followed for the entire admission.
Prior to commencing the audit we contacted the relatively few anaesthetists in Australia who work in this specialised area to reach general agreement about perioperative transfusion practices. We suggested, but did not stipulate, that participating anaesthetists follow guidelines for red blood cell transfusion that have been used in previous studies of paediatric cranioplasty 5, 6 , which can be summarised as: • In a stable patient, with no evidence of hypoxaemia or hypovolaemia: Do not transfuse until the measured haemoglobin (Hb) is less than 7 g/dl or the haematocrit is less than 21%. • In an unstable or actively bleeding patient, transfuse at the discretion of the treating team. Participants documented whether or not these guidelines had been followed. No suggestions were made about the use of other blood products.
One anaesthetist in each of the seven major centres undertaking these procedures acted as the local co-ordinator of the project and ensured that every eligible operation was included in the audit.
A form was completed for each case, coded at the home hospital and sent to the principal investigator without identifying details. Data recorded included the following: • Patient age, weight, previous craniofacial surgery. • American Society of Anesthesiologists physical status score, with comments justifying a score above II. • Hb on admission and at discharge. • Use of invasive monitoring, cell salvage and antifibrinolytic drugs. • Details of the blood products to which the patient was exposed. • The operation performed, classified as one of spring cranioplasty (SC), cranial vault reconstruction (CVR), fronto-orbital advancement (FOA) and posterior vault cranioplasty (PVC). • Duration of surgery. • Major complications throughout the entire admission, including death, cardiopulmonary resuscitation, hyponatremia (sodium less than 130 mmol/l), hyperkalemia requiring intervention, and stopping a blood transfusion due to a suspected transfusion reaction. The local co-ordinators recorded the number of units transfused (and hence the number of donors to whom the patient was exposed) rather than the volume of each unit transfused. We performed estimates of the blood volume lost (EBVL) to allow comparison between our audit and previous studies that have not documented donor exposure. We used the formula described by Kearney et al 7 , as follows: • Estimated red cell mass (ERCM)=EBV×haematocrit/100 • ERCM deficit=ERCM preop+ERCM transfused -ERCM postop. • EBVL=ERCM deficit/ERCM preop.
EBV was estimated as 80 ml/kg in children less than 12 months of age and 75 ml/kg in children over 12 months of age. To estimate the ERCM transfused, we assumed that each unit had a haematocrit of 60%, a volume of 256 ml and that the entire amount of each unit had been transfused. These estimates are based on a sample of 5490 episodes of quality control testing performed throughout the year of 2008 across all states and territories of Australia (Dr M. Borosak, personal communication). Data were analysed using Excel (Microsoft Corp, Redmond, WA, USA) and OpenEpi software 8 .
RESULTS
The hospitals where operations were performed are listed in Table 1 . As the Mater Children's and Royal Children's Hospitals in Brisbane have team members in common, their patients were grouped for display and analysis of results. Data from each hospital were de-identified and the hospitals were coded from A to F. Each participating hospital received their identified data.
Data were obtained on 132 patients. Two patients undergoing cranioplasty for reasons other than craniosynostosis were excluded. Two patients in the SC group underwent removal of springs; blood loss was minimal in both cases and invasive monitoring was not used in either case, so these cases were also excluded. One patient was transfused postoperatively outside the recommended guidelines and so this case was also excluded. No patient was included twice in the study period. After exclusions, data from the remaining 127 patients were audited.
The number of cases, average age and average weight for each operation at each hospital are summarised in Tables 2 and 3 . The median duration of surgery for SC was 1 hour 35 minutes (interquartile range [IQR] 1.05 to 2.00), compared with 3 hours 20 minutes for FOA (2.45 to 4.30) and 4 hours 20 minutes for CVR (2.40 to 5.10).
Blood loss and exposure to blood products
The median EBVL for SC was 33% (IQR 25 to 88%), compared with 88% for FOA (71 to 131%), and 92% for CVR (67 to 135%). The EBVL was greater than 100% in 14% of SC, 36% of CVR and 36% of FOA patients. The EBVL was greater than 200% in 4% of CVR and 11% of FOA patients (Table 4) .
Eighty-three percent of patients received a red blood cell (RBC) transfusion, including all CVR, all PVC and 98% of FOA, but only 32% of SC. The hospitals that performed the most SC had the lowest transfusion rates. Hospitals C and E performed a total of 21 SC, of whom only four patients were transfused (19%), whereas 6 of the 10 patients performed at hospitals A, D and F were transfused (60%). No patient undergoing SC received fresh frozen plasma, cryoprecipitate or platelets (haemostatic blood products [HBP]). Fifty percent of CVR patients received one RBC unit, 39% two units and 11% more than two units, with an average of 1.7 units per patient. One patient received four units. Forty-six percent of CVR patients received HBP, ranging from none of the six patients at hospital A to 10 of the 14 patients at hospital D (71%). The average number of donor exposures per patient was 2.4, with 36% exposed to only one donor.
Sixty-two percent of FOA patients received no or one RBC unit, 23% two units and 15% more than two units, with an average of 1.6 units per patient. Five patients received four or more units. Thirtytwo percent received HBP, ranging from none of the eight patients at hospital E to five of the nine patients at hospital C (56%). The average number of donor exposures per patient was also 2.4, with 60% exposed to no more than one donor.
Four CVR and 15 FOA patients had a recognised craniofacial syndrome or were undergoing repeat surgery (in one instance both). They received an average of 2.4 RBC units, compared to 1.4 units in other patients. Only 40% of this group received no more than one RBC unit. Fifty-three percent received HBP, compared to 22% of patients with other patients. Their median EBVL was 109% (IQR 82 to 200%), compared with 88% (71 to 131%) in other patients.
Invasive monitoring
An arterial line was used in 38% of SC (ranging between 100% at hospital F and 0% at hospital E), 100% of CVR and 100% of FOA patients. A central venous line was used in 25% of SC (ranging between 100% at hospital D and 0% at hospitals C and E), 89% of CVR and 58% of FOA patients. A urinary catheter was used in 28% of SC, 82% of CVR and 88% of FOA patients.
Major complications
There were no deaths and no requirement for cardiopulmonary resuscitation. Two hundred and thirty-three units of blood products were transfused, but no transfusion reactions were reported. There were two cases of massive haemorrhage attributed to dural venous sinus tear. One was a patient with a recognised craniofacial syndrome in whom CVR was planned, but the operation was converted to a modified FOA due to haemorrhage. This patient is classified as CVR for data analysis. The other occurred in a patient with an idiopathic synostosis undergoing FOA.
One infant undergoing repeat FOA suffered hyponatraemia, requiring re-intubation and prolonged ventilation. One infant undergoing FOA became hyperkalaemic in the operating theatre after three units of non-irradiated blood, all of which were less than five days old. Other than a moderate metabolic acidosis, no cause for hyperkalaemia in this patient was identified. No major complications were recorded for patients undergoing SC.
DISCUSSION
The potential blood loss in paediatric craniofacial surgery can be so large that it is often measured in blood volumes lost 2, 9 . Blood loss is difficult to measure with precision, and the volume of blood transfused is often used as a surrogate marker of blood loss. This volume is influenced not only by the patient's clinical state, but also by the clinician's opinion of when and how much to transfuse. One unit of packed red blood cells is a large dose in a child less than 24 months of age. The average EBV of children in our audit was 687 ml, and one RBC unit in Australia contains almost 40% of this volume. Some anaesthetists might only transfuse until an adequate circulating blood volume is restored, whereas others might transfuse beyond a child's immediate requirements in anticipation of ongoing blood loss, in order to minimise the likelihood that a further unit is required. Both approaches are logical and defensible, but have the potential to confound studies where the blood volume transfused, as a surrogate endpoint for blood loss, is the main outcome measure.
We chose instead to record the number of units transfused, and hence the number of donors to whom the patient was exposed, as well as the Hb at the start and end of the hospital admission. Each of these can be recorded with relative ease and accuracy. This information helps tranfusion medicine services to order appropriate products for each operation. As small amounts of blood can transmit viral and other infections, the infective risks of blood transfusion are more closely related to the number of donors to whom the patient is exposed than the volume transfused from each unit 10, 11 . It is also arguable that surgical or anaesthetic techniques that reduce blood loss are even more valuable if they also reduce the total number of donor exposures. Nevertheless, the risk of transmission of viral and other infections is currently exceedingly low (<1:500,000 RBC units exposures) 12 .
Exposure to blood products
Blood loss can also be extremely rapid, especially from dural venous sinus tears, which have been reported in 1 to 3% of cases 4, 13 and occurred in 2/127 cases in this series. Anaesthetists must respond quickly to actual or anticipated bleeding, often without waiting for laboratory results to confirm clinical estimates of blood volume lost. If a certain operation is known to have a high likelihood of transfusion, a surgical team might initiate transfusion earlier in a potentially unstable patient, whereas if the likelihood is low, the team might be more likely to wait for blood test results 7 . We found that SC patients were unlikely to require transfusion, especially in hospitals more experienced in the operation, but that all other craniosynostosis patients were highly likely to require at least one RBC unit. Patients with recognised craniofacial syndromes and those undergoing repeat surgery were more likely to be exposed to a second unit and to HBP. Increased blood loss has previously been reported in patients with recognised craniofacial syndromes 14 .
Patients with scaphocephaly (premature fusion of the sagittal suture) can be treated with either SC or CVR. SC is a relatively new operation, involving an incision along the fused suture and insertion of U-shaped springs that exert a constant force of 10 N. It is a relatively short operation and can usually be performed without a blood transfusion 15 . A second, smaller operation is required three to six months later for removal of the springs. A 2003 study comparing SC with CVR found that the mean blood loss in SC was 48 ml (confidence interval 29 to 83 ml), compared with 291 ml for CVR (confidence interval 230 to 352 ml). No child having SC was transfused or sent to the intensive care unit, whereas all CVR children were transfused and sent to intensive care. Children undergoing SC spent one less day in hospital. Surgical time for CVR was longer than the combined times of insertion and removal of springs 16 .
Our findings showed a similar contrast between SC and CVR. We found that the median EBVL for CVR was almost three times that of SC. All CVR patients were transfused, 50% received at least two RBC units and 46% received HBP, whereas only 32% of SC patients were transfused and none received HBP. This contrast was most apparent in hospitals where SC was performed more frequently (C and E), where only four of 21 SC patients (19%) were transfused. Potential advantages of CVR over smaller operations for scaphocephaly have been previously described 17 .
Invasive monitoring
Major haemorrhage leads to major metabolic disturbances, with development of metabolic acidosis. A base deficit range from -3 to -20 (median -9) has been demonstrated in children undergoing major craniofacial surgery, with a median time to return to normal of 9.25 hours (range 0 to 18) 16 . In our opinion, invasive monitoring in such cases is clearly justifiable. We found that arterial lines were used in most cases, but fewer central venous lines were placed in FOA patients than CVR patients. (Although the majority of FOA patients were exposed to no more than one donor, a higher proportion of FOA patients than CVR patients required at least three RBC units or lost more than two blood volumes, and there was no significant difference in overall blood product exposure between the two operations). One FOA patient suffered massive intraoperative haemorrhage from a sagittal sinus tear, requiring 12 donor exposures and a prolonged stay in intensive care. Three further FOA patients bled excessively during the operation and required at least nine donor exposures. Another bled postoperatively and returned to the operating theatre, ultimately requiring seven donor exposures. These cases demonstrate that sudden and potentially catastrophic bleeding can occur with both CVR and FOA. Central venous lines have become standard monitoring for all major cranioplasties at another hospital, as a result of a similar audit 2 .
Comparison with other studies
Most cranioplasties for craniosynostosis are performed in Australia in children up to 24 months of age. This is also the age where the head is proportionally largest in comparison with the rest of the body. By the time a child reaches two years of age, the brain and skull are 80% of adult size, but the total blood volume is only 20% of the adult value. We performed a calculation of EBVL to allow comparison with other studies of blood loss in paediatric craniofacial surgery. Most other studies have included older children, whose relatively smaller head and larger body make average blood loss as a percentage of estimated blood volume lower 2, 5, 6, 19, 20 .
We found that the mean and median EBVL in FOA patients was 117% and 88% respectively, with on average 1.6 RBC unit exposures per patient and 32% receiving HBP. EBVL in FOA has previously been reported as 116%, with a mean of two RBC units transfused and 28% needing HBP 14 . Another study reported an average blood loss for FOA as 91% 21 .
A recent review of the records of all patients who underwent craniofacial surgery in a five year period at the Children's Hospital of Philadelphia 2 included 159 patients aged between 1.5 months and 18 years, and included 129 FOA. EBVL greater than one and two blood volumes was reported in 57 and 10% of patients respectively 2 . In our FOA group, EBVL was greater than one and two blood volumes in 25 and 11% respectively. The incidence of other complications in this study was also similar to the incidence in our audit. Duncan and colleagues reported that EBVL in FOA in the United Kingdom averaged 132%, and then introduced a strict protocol for blood product use, similar in many ways to the one used in our study; a subsequent audit showed that EBVL had reduced to 46 to 50% 18 .
Cell salvage, antifibrinolytic agents and preoperative erythropoietin (EPO), with or without iron, have all been shown to reduce blood transfusion requirements in paediatric craniofacial surgery 5, 6, 17, 20, 22 .
Using both EPO and cell salvage has been shown to reduce the perioperative transfusion rate from 100 to 5%; children receiving preoperative EPO had a mean preoperative haematocrit of 38.9 after three doses, compared with 25.6 in the control group 23 . Another small study investigated the use of preoperative EPO with iron and acute preoperative normovolaemic haemodilution, achieving a transfusion rate of 31% in the study group, compared with 77% in the control group; a mean of 17.7 ml/kg of autologous blood was collected preoperatively in the study group 24 .
No Australian hospital used EPO for paediatric craniofacial patients in 2008. Infants receiving EPO must have regular blood tests and injections in the weeks leading up to surgery. Several authors have emphasised that although EPO is an effective agent, the cost and complexity of its administration may be prohibitive 5, 20, 25 . Based on our audit, there seems little need to administer EPO to SC patients. The hospitals with the greater experience in SC had lower blood loss figures without using EPO, cell salvage or antifibrinolytic agents. Surgical teams who perform fewer SC cases might benefit from comparing their practice with teams from hospitals C and E.
EPO, antifibrinolytics and cell salvage may have a greater potential role in CVR and FOA patients. The cost of EPO might be offset by restricting its administration to patients who are already close to avoiding transfusion; based on our audit, this would be children without a recognised syndrome undergoing primary FOA or CVR.
Antifibrinolytic agents and cell salvage are potentially less costly than blood transfusion. Only hospital D used antifibrinolytics and only D and E used cell salvage, yet 62% of FOA patients received no more than one RBC unit and were discharged with a median Hb of 9.7 g/dl (IQR 8.6 to 11.3). It seems reasonable to expect that either strategy might help avoid transfusion in more cases than occurs at present. Hospital A appears closest to this target; without using any of these strategies, 57% of CVR patients and 64% of FOA patients received no more than one RBC unit, and were discharged with a median Hb of 12.5 (IQR 10.6 to 13.9) g/dl.
Use of haemostatic blood products
Massive haemorrhage can be defined as one blood volume loss in less than 24 hours. Recent studies of massive haemorrhage in the setting of trauma have highlighted the benefits of early transfusion of HBP 26 .
Coagulopathy in paediatric cranioplasty is also most significant when EBVL exceeds one blood volume. In a study of the evolution of coagulopathy, 27 children undergoing cranioplasty did not receive HBP until the end of surgery, at which time clotting studies were performed. Those in whom EBVL was less than 100 ml/kg were not coagulopathic (median EBVL 92%, International Normalised Ratio 1.2), whereas those in whom EBVL was greater than 100 ml/kg were coagulopathic (median EBVL 190%, International Normalised Ratio 1.5). The coagulopathy was thought to be dilutional. The platelet count in each group was within normal limits 9 .
Other studies have found no difference in transfusion rate, postoperative bleeding or time spent in the intensive care unit between the use of albumin or fresh frozen plasma (FFP) in cranioplasty operations where blood loss is less than one blood volume 28, 29 .
In a retrospective review of cranioplasty patients at the Children's Hospital of Philadelphia, coagulopathy was found to be more likely where EBVL routinely exceeded one blood volume 2 . They also reported an association between albumin transfusion and coagulopathy, although their study was not able to differentiate between dilutional coagulopathy and an effect directly attributable to albumin itself. They now use matched donor RBC and FFP units, which are reconstituted and used before coagulopathy develops. This has eliminated the need for albumin and reduced the mean number of donor exposures from three (in the historical control) to two 25 . Postoperatively, they also found less deranged postoperative coagulation studies, less transfusion requirements, but no change in surgical drain output in the reconstituted matched donor group. The authors do point out that transfusionrelated acute lung injury has been more commonly reported with FFP than other blood products. Based on our EBVL calculations, only 36% of CVR and FOA patients were likely to develop coagulopathy, and so prophylactic FFP for all patients does not appear warranted. Furthermore, Australian guidelines for massive transfusion do not support the use of FFP until the International Normalised Ratio is greater than 1.5 30 .
CONCLUSIONS
This national audit reinforces previous observations that blood loss in paediatric cranioplasty can be both sudden and extensive. As with all audits, the findings are descriptive, and the major inferences are hypothesis generating rather than hypothesis confirming. Nevertheless, the findings may inform choices in relation to the management of cranioplasty for craniosynostosis, or at least be the basis for prospective studies.
